|
Adult Acute Lymphocytic Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that polymorphic variants in the CYP1A1*4 gene may increase the risk of childhood ALL, particularly in male patients aged 2-10 years.
|
23725389 |
2014 |
|
Adult Acute Lymphocytic Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, TPMT*2, TPMT 719*G and CYP1A1*2 variants did not appear to influence ALL susceptibility (p > 0.05).
|
23065291 |
2013 |
|
Adult Acute Lymphocytic Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The overall data indicated a significant association of CYP1A1 MspI polymorphism with ALL risk (CC+TC vs TT: OR=1.33; 95%CI=1.05-1.69).
|
22964275 |
2012 |
|
Adult Acute Lymphocytic Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our study provides a novel and specific link between CYP1A1 polymorphisms and ethnic influence on ALL risk that may help explain varying susceptibilities across groups to environmental toxins.
|
21586621 |
2011 |
|
Adult Acute Lymphocytic Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These data indicate that the CYP1A1*2A genotype contributes significantly to susceptibility to adult ALL in a sample of the Mexican population.
|
18203634 |
2008 |
|
Adult Acute Lymphocytic Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There was an increased frequency of the CYP1A1 Val/Val genotype among ALL patients, showing a significant association between this genotype and the risk of developing ALL.
|
15528152 |
2005 |
|
Adult Acute Lymphocytic Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, when the mutant CYP1A1 and CYP2E1 alleles were considered together with the GSTM1 and GSTP1 risk-elevating genotypes, the risk of ALL was increased further (OR = 10.3; 95% CI = 1.0-111.8; P = 0.05), suggesting a combined effect.
|
14991750 |
2004 |
|
Adult Acute Lymphocytic Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Homozygous CYP1A1*2A genotype was underrepresented in ALL patients (1%) as compared to control (4.8%) but the differences did not reach to statistical significance (OR 0.21; 95% CI 0.03-1.72).
|
12827651 |
2003 |
|
Adult Acute Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
When NAT2 slow acetylators were considered together with the other risk-elevating genotypes, GSTM1 null and CYP1A1*2A, the risk of ALL increased further, which showed that the combination of these genotypes is more predictive of risk then either of them independently.
|
10868688 |
2000 |
|
Adult Acute Lymphocytic Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The NAT2 slow-acetylator, CYP1A1*2A and GSTM1 null genotypes were shown to be significant risk determinants of ALL (OR=1.6, 1.8 and 1.8, respectively), whereas, polymorphisms in CYP2D6 and GSTT1 genes did not seem to play an important role in the aetiology of ALL.
|
10953966 |
2000 |
|
Adult Acute Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Unexpectedly, girls carrying the CYP1A1*4 were significantly underrepresented in the ALL group (OR = 0.2), suggesting that a gender-specific protective role exists for this allele.
|
10029576 |
1999 |
|
Adult Acute Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We determined lymphocyte aryl hydrocarbon hydroxylase (AHH) inducibility for members of 13 families with one or more children with acute lymphoblastic leukemia (ALL) and 12 control families.
|
2796383 |
1989 |